Mr. Speaker, it is a pleasure to address the House today to speak on the third and final reading of Bill C-307, the proposed phthalate control act.
When the government took a look at the original bill, it was badly written and, quite frankly, was not a good legislation. However, I am happy to see that the government was able to significantly amend the bill into a form we could support.
As my hon. colleagues have already advised the House, our government supports Bill C-307 in its amended state.
The amended bill would ensure that the substances under consideration, known as BBP, DBP and DEHP, would continue to be managed through the existing process for dealing with substances that may pose a threat to the environment and to human health.
At the second reading debate, the government expressed concern that Bill C-307, as originally drafted, would circumvent the comprehensive scientific assessment of phthalates, by imposing an immediate and outright ban on the use of BBP, DBP and DEHP.
I am very pleased that the hon. member for Skeena—Bulkley Valley has acknowledged the government's concerns and agrees to respect the scientific assessment process provided for under the Canadian Environmental Protection Act, 1999, otherwise known as CEPA.
As we have heard today, the federal Departments of Environment and Health have already assessed the risks associated with the three subjects named in Bill C-307. Actions have been taken, where warranted.
Having said that, the government fully supports the reassessment of BBP and DBP within the next two years, provided that these assessments use the appropriate process, the CEPA review mechanism. We are also prepared to support additional regulatory measures to strengthen control of DEHP, which has been proven to have associated health risks.
Both of these measures are included in Bill C-307 and are consistent with the government's commitment to protect human health and the environment, as reiterated in the recent Speech from the Throne. They are also consistent with the government's chemical management plan, which I will discuss in more detail shortly.
I am pleased to confirm that Bill C-307 no longer subverts CEPA, which provides the framework for identifying, prioritizing and assessing existing substances for controlling or managing those considered to pose a risk to Canadians or the environment.
One of the stated goals of CEPA is to manage risk from substances. This recognizes the reality that, from time to time, we will come across substances that may pose a threat to the environment or to health but that also offer important benefits.
DEHP is such a substance. There are health concerns associated with human exposure, but a ban on DEHP could create severe problems for the medical community as there are currently no viable alternatives for this plasticizer in certain medical devices.
CEPA's management process relies on scientific evidence and comprehensive research and monitoring programs. The science around phthalates is constantly evolving, so we welcome the reassessments of BBP and DBP called for in the bill, Bill C-307, as they will help build our knowledge and support sound decision-making.
One particularly important aspect of the CEPA process is that the public and interested groups are given adequate notice about risk assessments that are planned or underway. They have also the opportunity to comment on the results before decisions are made. This public involvement element was lacking in Bill C-307 as originally presented to this House.
CEPA also allows for some flexibility in terms of risk management responses, taking into account not only environmental and health issues, but also social, economic and technological factors. Regulations are sometimes the answer, but not always. For example, Bill C-307 would provide for the development of clinical practice guidelines for using medical devices that contain DEHP.
The government is committed to working with all our partners to ensure that Canada is at the forefront of international chemicals management and that our citizens and our environment is protected.
Last December, we unveiled a chemicals management plan. This plan provides for immediate action to regulate chemicals that are harmful to human health or the environment, and is a key element of our government's comprehensive environmental and human health agenda. We have committed $300 million over four years to implement the chemicals management plan, which will build on Canada's position as a global leader in the safe management of chemical substances and products.
Taking action now will significantly reduce future costs associated with water treatment, the clean up of contaminated sites and treating illnesses related to chemical exposure. It will improve the quality of life of Canadians and better protect our environment. This plan will also improve the conditions for business in Canada by ensuring a level playing field and a predictable, science based regulatory regime.
It provides for strengthened regulations and enforcement, restrictions on reintroduction and new uses of controlled substances, rapid screening of lower risk chemical substances, accelerated re-evaluation of older pesticides, mandatory ingredient labelling of cosmetics, regulations to address environmental risks posed by pharmaceuticals and personal care products, enhanced management of environmental contaminants in food, health monitoring, surveillance and research, increased risk communications to the public and good stewardship of chemical substances.
Under the umbrella of the chemicals management plan, our government has developed a comprehensive strategy for phthalates that includes many of the measures provided for in Bill C-307. An example of that is the phthalate strategy includes reassessments of BBP and DBP under CEPA, the implementation of controls to protect children under the age of three and the development of clinical practice guidelines for medical devices containing DEHP. It also provides for the addition of DEHP to Health Canada's cosmetic ingredient hot list, as well as the assessment and risk management of other phthalates in cosmetics.
As part of the reassessment process, the government will be reviewing the scientific evidence used to support recent regulatory actions taken by the European Union on DEHP, BBP and DBP, among other phthalates. Our government will also continue to monitor the evolving science on the use of DEHP in medical devices and will take further actions, as required. I should point out that none of Canada's major trading partners, including the European Union, has prohibited DEHP in medical devices such as blood bags and intravenous tubes.
Our government will continue to monitor 11 phthalate metabolites and 8 parent phthalate compounds as part of the Canadian health measures survey. In addition, phthalates will be included in a proposed bio-monitoring study for children from birth to six years of age. Data from these studies will inform any future actions by the government.
In short, our government is already taking comprehensive action to assess and control phthalates and other potentially harmful substances. Because amended Bill C-307 is consistent with these actions and with our government's overall commitment to protecting Canadians and their environment, we will vote in favour of this legislation.